Published in Gene Therapy Weekly, July 25th, 2002
"Rubicon OmniPlex WGA will change the structure of population studies and clinical trials, decreasing the cost and time for drug development," stated Thomas A. Collet, president and CEO of Rubicon Genomics. "Many of the large-scale population and clinical single nucleotide polymorphism (SNP) studies have encountered hurdles due to the lack of sufficient DNA to score...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.